Ensign Peak Advisors, Inc Nkarta, Inc. Transaction History

Ensign Peak Advisors, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.37 - $6.3 $228,657 - $427,461	-67,851 Reduced 70.59%	28,265 $100,000
Q3 2022 Nov 14, 2022	BUY	$12.27 - $18.39 $159,215 - $238,628	12,976 Added 15.61%	96,116 $1.27 Million
Q2 2022 Aug 12, 2022	BUY	$7.77 - $19.44 $270,271 - $676,200	34,784 Added 71.93%	83,140 $1.02 Million
Q4 2021 Feb 11, 2022	BUY	$12.79 - $26.88 $113,063 - $237,619	8,840 Added 22.37%	48,356 $743,000
Q3 2021 Nov 12, 2021	BUY	$26.67 - $38.76 $547,375 - $795,510	20,524 Added 108.07%	39,516 $1.1 Million
Q1 2021 May 12, 2021	BUY	$31.33 - $59.61 $293,718 - $558,843	9,375 Added 97.48%	18,992 $625,000
Q3 2020 Nov 12, 2020	BUY	$23.52 - $47.9 $226,191 - $460,654	9,617 New	9,617 $289,000

126

66.5M

173K

20K

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $121M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.